Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 499 across all filing types
Latest filing 2022-06-16 Regulatory Filings
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
NICE rekommenderar Hansa Biopharmas läkemedel Idefirix® (imlifidase) för desensitiseringsbehandling av högsensitiserade njurtransplantationspatienter
Regulatory Filings Classification · 95% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces that NICE (National Institute for Health and Care Excellence) has recommended Hansa Biopharma's drug Idefirix®. It details the significance of this recommendation for patient access and mentions regulatory approvals (MHRA, EMA). The text is a formal announcement of a business/regulatory event, not a comprehensive financial report (like 10-K or IR), a transcript (CT), or a specific regulatory filing form. Since it is a formal announcement regarding a regulatory/market development, and it doesn't fit the specific categories like DIV, DIRS, or CAP, it falls best under the general category for regulatory announcements or news releases that don't fit elsewhere, which is RNS (Regulatory Filings/General Regulatory Announcements). The document length (10,814 chars) is substantial, suggesting it is the primary content, not just a brief announcement of a report (which would suggest RPA).
2022-06-16 Swedish
NICE recommends use of Hansa Biopharma’s Idefirix® (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
Regulatory Filings Classification · 98% confidence The document is explicitly titled '# PRESS RELEASE' and announces that NICE (National Institute for Health and Care Excellence) has recommended Hansa Biopharma's Idefirix®. It details the clinical and cost-effectiveness findings supporting this recommendation. The text structure, including quotes from executives and patient advocates, references to regulatory bodies (NICE, MHRA, EMA), and concluding with contact information for Investor Relations and Corporate Communications, strongly indicates this is an official announcement of a significant business/regulatory event, rather than a full financial report (like 10-K or IR) or a transcript. Since it is a press release announcing a positive regulatory/reimbursement decision, it fits best under the general 'Regulatory Filings' category (RNS) as a broad announcement, although it shares characteristics with an Earnings Release (ER) if it were tied to quarterly results. Given the focus is purely on the NICE recommendation and not financial performance highlights, RNS is the most appropriate general regulatory announcement category for non-standard filings.
2022-06-16 English
Hansa Biopharma: Notice to Annual General Meeting
AGM Information Classification · 100% confidence The document is explicitly titled "Hansa Biopharma: Notice to Annual General Meeting" and details the date, procedures (advance voting only), and the proposed agenda for the meeting. The agenda items cover the election of the chair, board members, auditors, approval of financial statements, and proposals regarding remuneration and incentive programs. This content directly corresponds to the purpose of an Annual General Meeting notice and related materials. Therefore, the classification is AGM-R (AGM Information).
2022-05-30 English
Hansa Biopharma: Kallelse till årsstämma
AGM Information Classification · 98% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and its main subject is "Hansa Biopharma: Kallelse till årsstämma" (Hansa Biopharma: Notice of Annual General Meeting). It details the procedures for the upcoming Annual General Meeting (AGM) on June 30, 2022, including instructions for advance voting (förhandsröstning), the proposed agenda (Förslag till dagordning) covering board elections, remuneration, and incentive programs, and proposals from the Nomination Committee and the Board. This content is characteristic of a formal notice and materials related to an AGM, which aligns directly with the AGM Information category (AGM-R). Although it contains proposals that might appear in other filings, the primary purpose and framing are for the shareholder meeting.
2022-05-30 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT JANUARI-MARS 2022' (Interim Report January-March 2022). It contains comprehensive financial tables (Nettoomsättning, Rörelseresultat, etc.) for the first quarter of 2022, alongside detailed management commentary, clinical pipeline updates, and operational highlights. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-04-21 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY-MARCH 2022' and contains comprehensive financial data, including a summary table for Q1 2022 vs Q1 2021, management commentary, and detailed operational updates. It is a full quarterly report rather than a brief announcement or a standalone audit, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-04-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.